Gyre Therapeutics: Advancing Immuno-Oncology with Promising VISTA Antibody Trial Results
- Gyre Therapeutics is focused on innovative immuno-oncology treatments, benefiting from insights from recent clinical data.
- The VISTA-101 trial shows KVA12123 has over 90% VISTA receptor occupancy, indicating strong efficacy for solid tumors.
- Results from VISTA-101 suggest a well-tolerated treatment, influencing future immuno-oncology studies and potential Phase 2 trials.
VISTA Antibody Trial Advances Immuno-Oncology Landscape
Gyre Therapeutics focuses on the development of innovative treatments in the field of immuno-oncology, an area that gains significant insights from recent clinical data shared at the American Association for Cancer Research (AACR) Annual Meeting. Kineta Inc. presents promising results from its VISTA-101 trial, evaluating KVA12123, a novel anti-VISTA antibody. The trial showcases over 90% VISTA receptor occupancy at the 1,000mg bi-weekly dose, a significant achievement in understanding the efficacy of VISTA-targeting therapies. The findings, delivered by Chief Scientific Officer Thierry Guillaudeux, highlight KVA12123's potential as both a standalone treatment and in combination with the checkpoint inhibitor pembrolizumab for patients with advanced solid tumors.
The VISTA-101 trial is structured as a Phase I-II study, assessing KVA12123's safety and effectiveness among 41 patients. Notably, the results indicate that the treatment is well-tolerated, with no dose-limiting toxicities reported in the cohort receiving monotherapy or those treated in combination with pembrolizumab. The pharmacokinetic (PK) and pharmacodynamic (PD) profiles observed suggest that a reduced dose of 750mg bi-weekly might be appropriate for subsequent Phase 2 trials. This information could significantly influence future studies and the broader landscape of immuno-oncology therapies, particularly in treating solid tumors that resist traditional therapies.
The growing interest in VISTA (V-domain Ig suppressor of T cell activation) stems from its potential role in promoting immunologic tolerance, which could be transformative for treating various blood-related cancers. As Kineta prepares for a merger with TuHURA Biosciences, which is anticipated to finalize by the end of Q2 2025, the data from the VISTA-101 trial becomes increasingly vital. The exclusivity payment made by TuHURA last July facilitated the completion of this significant study, underscoring the collaboration's potential to advance therapeutic options in immunotherapy.
In addition to Kineta’s promising findings, TuHURA Biosciences also presents data on its Phase 3-ready IFx2.0 therapy, demonstrating substantial anti-tumor responses in advanced melanoma patients who did not respond to prior checkpoint inhibitor treatments. This dual focus on VISTA and innovative therapies like IFx2.0 indicates a robust commitment to enhancing treatment protocols in immuno-oncology, reflecting the industry's ongoing evolution and the need for collaborative efforts to tackle challenging cancer types.